Want to learn more? Check out our

What’s the Difference Between IIH and Pseudotumor?

IIH is only one of multiple conditions that may lead to pseudotumor cerebri

It is important to understand that IIH is only one of multiple conditions that may lead to pseudotumor cerebri. Thus, some cases of pseudotumor are truly without an identifiable cause (hence the term idiopathic in IIH). However, in other cases, patients may meet the diagnostic criteria of pseudotumor but have a known association (such a medical condition or use of a medication) with a pseudotumor cerebri diagnosis. In these cases, depending on the condition or medication, treatment of the medical condition or removal of the medication may improve the patient’s symptoms.

Known as the modified Dandy criteria, the diagnostic criteria for IIH was revised in 1985, from its original version in the 1930s. Four fundamental features are required to establish the diagnosis of IIH:

Symptoms consistent with increased intracranial pressure: headaches, vomiting, and nausea. Visual signs and symptoms such as blurriness, transient obscurations of vision, and papilledema.

  1. Normal neurological exam with the exception of unilateral or bilateral cranial VI nerve paresis.
  2. Elevated opening pressure on lumbar puncture (greater than 250 mm) and normal analysis of cerebrospinal fluid.
  3. Normal imaging of the brain.₁
  1. https://n.neurology.org/content/59/10/1492

Related articles

Omar Choudhri, MD
March 7, 2024
Dr. Omar Choudhri discusses the factors that contribute to the pathophysiology of IIH and advanced imaging to help aid in the diagnosis...
December 14, 2023
Dr. Plenty discusses the importance in understanding how these two conditions are interrelated, as over 95% of people affected with IIH are women ...

Stay Informed

Stay up-to-date on the latest research and resources on this Hub by subscribing to our monthly newsletter

Like what you are seeing?

Join our next webinar.

Thank you! You’re registration is complete for:

IIH Practitioner Series

Join our June webinar to discuss GLP1’s and its impact on patients with obesity.

June 24 at 9:30 am ET